Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$138.48 USD
+2.33 (1.71%)
Updated May 14, 2024 04:00 PM ET
After-Market: $138.32 -0.16 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.48 USD
+2.33 (1.71%)
Updated May 14, 2024 04:00 PM ET
After-Market: $138.32 -0.16 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Zacks News
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.
Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.
Will Big Stocks Make Big Headlines? Global Week Ahead
by John Blank
This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.
Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns
by Vaishali Doshi
Here are four top-performing liquid stocks, Neurocrine Biosciences (NBIX), GigaCloud Technology (GCT), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for robust returns.
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDYG
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDYG
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
by Zacks Equity Research
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.